Navigation Links
Study uses new stem cell therapy in patients up to 19 days after stroke
Date:7/14/2011

HOUSTON (July 14) The first Texas patient has been enrolled by researchers at The University of Texas Health Science Center at Houston (UTHealth) in the country's first double-blind clinical trial studying the safety and efficacy of an innovative stem cell therapy that can be given up to 19 days after an ischemic stroke.

The Phase II study, cleared by the Federal Drug Administration, examines a regenerative therapy developed by Aldagen that uses a patient's own bone marrow stem cells. The therapy, called ALD-401, consists of stem cells that are identified using Aldagen's proprietary technology to isolate cells that express high levels of an enzyme that serve as a marker of stem cells.

Studies found that these cells enhance recovery after stroke in mice. The cells are administered into the carotid artery.

"This represents a new approach using stem cells for stroke," said Sean Savitz, M.D., senior investigator for the multi-center study and associate professor of neurology at the UTHealth Medical School. "A major question in the field of stem cell research is whether we can extend the time window for administering stem cells. A longer window increases the number of patients that might be helped."

Preclinical research, including research at UTHealth, has suggested that stem cells can promote the repair of the brain after an ischemic stroke, which is caused by a blood clot in the brain. Stroke is a leading cause of disability and the fourth-leading cause of death in the United States, according to 2008 statistics reported by the Centers for Disease Control and Prevention.

The Houston resident received either placebo or ALD-401 on June 8 at Memorial Hermann-Texas Medical Center after suffering a stroke May 23 while on a trip to California. Her stroke was caused by previously undiagnosed atrial fibrillation.

"We were waiting for our taxi at the hotel and I immediately couldn't talk and my husband said my face was drooping," said the 67-year-old cosmetics developer. "We were just three blocks from a major trauma center. I had an angel with me because if it had happened two hours later, I would have been on an airplane."

Once back in Houston, she was referred to Savitz' study by Erin Furr-Stimming, M.D., UTHealth assistant professor of neurology, who treats her for Parkinson's disease.

While she doesn't know whether or not she received the stem cells in the double-blind study, she didn't hesitate to join the trial.

"I did a lot of research on stem cells online. I was very excited when I heard about the trial. I wanted to participate in the research for me, if possible, and for other people behind me," she said.

Savitz and his research team are studying other stem cell therapies for acute stroke, and these must be administered within a few days of the stroke. One of those, a safety and efficacy trial using a patient's own bone marrow stem cells administered intravenously, is funded by the National Institutes of Health. UTHealth researchers in the Department of Pediatric Surgery also are studying the use of stem cells for pediatric traumatic brain injury.


'/>"/>

Contact: Deborah Lake
deborah.m.lake@uth.tmc.edu
University of Texas Health Science Center at Houston
Source:Eurekalert  

Related biology news :

1. Study challenges baby formula claim
2. Study explains why men are at higher risk for stomach cancer
3. First study into GM Atlantic salmon mating reveals danger of escape to wild gene pool
4. Your mother was right: Study shows good posture makes you tougher
5. Researchers study pesticide pathways into the atmosphere
6. Scleroderma study identifies roadblocks to employment
7. Study: People at risk for panic buffered from stressor by high levels of physical activity
8. UCI study points to new means of overcoming antiviral resistance in influenza
9. Owl study expands understanding of human stereovision
10. Virginia Tech Coal and Energy Center selected for study of CO2 injection into storage reservoirs
11. Large human study links phthalates, BPA and thyroid hormone levels
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study uses new stem cell therapy in patients up to 19 days after stroke
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed ... received the prestigious international IAIR Award for the most innovative high security ... ... Maldives Immigration Controller General, ... picture on the right) have received the IAIR award for the "Most ...
Breaking Biology News(10 mins):
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ex-FDA official ... trials comes to Tampa, San Francisco and Boston in 2017. The 2016 ... organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix Inc., Cell ...
(Date:4/26/2017)... ... April 26, 2017 , ... Baltimore ... Bioflash MailGuardtm mail security screening solution at the National Postal Forum 2017 in ... provides a fast, highly accurate, easy to use and low cost threat detection ...
(Date:4/26/2017)... RESTON, Va. (PRWEB) , ... April 26, 2017 ... ... to make headlines and drive high-level conversations among healthcare industry stakeholders, the discussion ... Healthcare Environment – taking place May 15-18, 2017 in Los Angeles, Calif. Hosted ...
(Date:4/25/2017)... ... , ... As part of the Stago EdVantage Virtual University Virtual ... in order to illuminate this clinical problem for people unfamiliar with the topic. , ... a high degree of morbidity and mortality. DIC is a confusing disorder from both ...
Breaking Biology Technology: